The challenges and opportunities in cancer drug development come down to this: How do we most efficiently and effectively capitalize on the evolving understanding of cancer biology to transform care?

Researchers reportedly observed reductions in tumor size and slowed tumor progression—in the range from 60 to 80 percent.

But since 2010, cancer drugs have claimed 27% of new approvals—a share that doubled over the previous decade—according to a new report from the Tufts Center for the Study of Drug Development.

In September 2022, the Accelerating Anticancer Agent Development and Validation workshop was held, focusing on global cancer drug development.

Russia has unveiled a groundbreaking development in oncology with Enteromix, a personalized mRNA-based cancer vaccine that ...

The findings challenge long-standing assumptions about therapy-related cancers. They also highlight how drug actions can substitute for genetic changes in tumor development. An international team of ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Thyroid Cancer Pipeline Report to explore emerging ...

As a cancer doctor I know firsthand this dismal statistic that speaks for itself: Only about 1 in 20 promising cancer drugs that enter the clinic ever win FDA approval.

Adoption of new cancer drugs requires careful consideration of their benefits, toxicities, and costs. Patient experiences are rarely considered in trial design and drug-approval processes. Challenges ...

Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from an early-stage trial showed the treatment was unlikely to benefit as a standalone therapy.

How cancer drugs find their targets could lead to a new toolset for drug development Date: June 19, 2020 Source: Whitehead Institute for Biomedical Research Summary: Cellular processes such as ...